Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Minimal long-term cardiac safety findings were reported with ozanimod treatment in patients with ...
Acalabrutinib demonstrates a favorable cardiovascular safety profile in CLL, with low cardiac failure rates compared to ibrutinib and chemoimmunotherapy. The selectivity of acalabrutinib reduces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results